Skip to main content
Toggle navigation
Login
Search
Home
Tweets by IDWeek 2023
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Peng Xiang, MD
Changsha Central Hospital, China, China
Poster(s):
(2519) A Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Saturday, October 14, 2023
12:15 PM – 1:30 PM
US ET
